Equities

Assembly Biosciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Assembly Biosciences Inc

Actions
  • Price (EUR)15.25
  • Today's Change-0.10 / -0.65%
  • Shares traded400.00
  • 1 Year change+36.16%
  • Beta0.6466
Data delayed at least 15 minutes, as of Jul 03 2025 18:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).

  • Revenue in USD (TTM)32.15m
  • Net income in USD-39.92m
  • Incorporated2005
  • Employees73.00
  • Location
    Assembly Biosciences IncTwo Tower Place, 7Th FloorSOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (212) 554-4388
  • Fax+1 (646) 706-5101
  • Websitehttps://www.assemblybio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.